To include your compound in the COVID-19 Resource Center, submit it here.

sterna's SB012 meets in Phase IIa data for UC

sterna biologicals GmbH & Co. KG (Marburg, Germany) said intrarectal SB012 met the primary endpoint of improving disease activity from

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE